International Consensus on the Clinical Management of Inflammatory Breast Cancer from the Morgan Welch Inflammatory Breast Cancer Research Program 10th Anniversary Conference.

about

International Consensus on the Clinical Management of Inflammatory Breast Cancer from the Morgan Welch Inflammatory Breast Cancer Research Program 10th Anniversary Conference.

Item

http://www.wikidata.org/entity/Q52714397

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

International Consensus on the ...... m 10th Anniversary Conference.

@en

International Consensus on the ...... m 10th Anniversary Conference.

@nl

type

Item

label

International Consensus on the ...... m 10th Anniversary Conference.

@en

International Consensus on the ...... m 10th Anniversary Conference.

@nl

prefLabel

International Consensus on the ...... m 10th Anniversary Conference.

@en

International Consensus on the ...... m 10th Anniversary Conference.

@nl

P1476

International Consensus on the ...... am 10th Anniversary Conference

@en

P2093

Angela Alexander

http://www.w3.org/2001/XMLSchema#string

Anthony Lucci

http://www.w3.org/2001/XMLSchema#string

Beth Overmoyer

http://www.w3.org/2001/XMLSchema#string

Dan Rea

http://www.w3.org/2001/XMLSchema#string

Edward Chang

http://www.w3.org/2001/XMLSchema#string

Fedor Berdichevski

http://www.w3.org/2001/XMLSchema#string

Gildy Babiera

http://www.w3.org/2001/XMLSchema#string

Huong T Le-Petross

http://www.w3.org/2001/XMLSchema#string

Jennifer Bellon

http://www.w3.org/2001/XMLSchema#string

Massimo Cristofanilli

http://www.w3.org/2001/XMLSchema#string

P2860

Inflammatory breast cancer: what we know and what we need to learn

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)

Intensive dose-dense compared with conventionally scheduled preoperative chemotherapy for high-risk primary breast cancer.

Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial.

Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40

Locoregional treatment outcomes after multimodality management of inflammatory breast cancer

Inflammatory breast carcinoma: mammographic, ultrasonographic, clinical, and pathologic findings in 142 cases.

Phase III comparison of standard doxorubicin and cyclophosphamide versus weekly doxorubicin and daily oral cyclophosphamide plus granulocyte colony-stimulating factor as neoadjuvant therapy for inflammatory and locally advanced breast cancer: SWOG 0

Confocal fluorescence microscopy for rapid evaluation of invasive tumor cellularity of inflammatory breast carcinoma core needle biopsies.

P304

1437-1447

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.7150/JCA.23969

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Jose Rodrigo Espinosa Fernandez

Mohamed El-Shinawi

Wendy A Woodward

Bora Lim

P577

2018-04-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29721054

http://www.w3.org/2001/XMLSchema#string

P932

5929089

http://www.w3.org/2001/XMLSchema#string